http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
C3H 생쥐에서 자외선 B의 집중조사와 분할조사가 표피내 랑게르한스 세포의 회복에 미치는 영향
구상완,한승경,박윤기,조무연 ( Sang Wahn Koo,Seung Kyung Hann,Yoon Kee Park,Moo Yon Cho ) 대한피부과학회 1991 대한피부과학회지 Vol.29 No.4
N/A The Effect on the Recovery of Epidermal Langerhans Cells in C3H Mice after Single and Fractionated Exposure of Ultraviolet B Irradiation Sang-Wahn Koo, M.D., Seung Kyung Hann, M.D., Yoon-Kee Park, M.D., Moo Yon Cho, M.D. Department of Dermatology, Yonsei University College of Medicine Seoul, Korea The study was undertaken to see the recovery in epidermal Langerhans cells in relation to time after UVB irradiation through different amounts and ways of exposure in C3H mice. We irradiated the ears of C3H mice with UVB 200mJ/㎤ and 400mJ/㎤ in a single dose at one time and 5 fractionated doses for 5 days and 10 fractionated doses for 10 days and performed biopsies on the ears of the control and experimental groups after, 2, 7, 14, 21 days of irradiation and stained them by the immunoperoxidase method. The results are summarized as follows. 1. A more significant decrease in the number of Ia-positive epidermal Langerhans cells was observed in single-dose-exposed group than fractionated-dose-exposed groups on the second day of irradiation. 2. On the seventh day of exposure, the number of the Ia-positive epidermal cells in single-dose-exposed group returned to normal, but in fractionated-dose-exposed groups the number of Langerhans cells decreased most remarkably. 3. In fractionated-dose-exposed groups, the number of Langerhans cells returned to normal on the 14th or 21st day of expposure. (Kor J Dermatol 29(4) : 459-465, 1991)
p21-activated kinase 1 is allostericallyInhibited by naphthoquinone (NQ) derivatives.
Sang-WonOh,Kee-InLee,Joong-KwonChoi,Kyung-AhKim,Eung-GookKim,Eun-YoungShin 충북대학교 동물의학연구소 2017 Journal of Biomedical and Translational Research Vol.18 No.2
The p21-activated kinases (PAKs) are a family of serine/threonine protein kinases and activated by binding with activated Rho GTPases such as Rac or Cdc42. PAKs regulate actin cytoskeletal remodeling, cell motility, cell survival, and apoptosis. Also, PAKs are involved in several diseases such as cancer, virus infectious diseases, mental retardation, Alzheimer and Parkinson's diseases. Therefore, the substances that are able to inhibit PAK activation can be used as powerful tools and medicines for PAK relative diseases or specific inhibitors for study of PAK signaling pathway. In this study, we investigated and characterized the 5 compounds of 4-benzene-1, 2-naphthoquinone (NQ) family as candidate substances to inhibit the PAK1 activation in vitro and in cells. Binding between p21-binding domain (PBD) of PAK1 and Cdc42 was blocked by 5 NQ-compounds in ELISA assay. Myelin basic protein (MBP) phosphorylation was dramatically reduced by treatment of these compounds in vitro kinase assay for Cdc42-induced or constitutive active PAK1 mutant. Also, phosphorylation at Thr 423 of transfected PAK1 was inhibited by treatment of 5 NQ-compounds in 293T cells, respectively. Finally, NQ-5 inhibited strongly the PAK1 activation by PDGF stimulation and cell motility in PDGF-induced wound migration assay in NIH 3T3 cells. Therefore, these NQ compounds will be good candidates as target molecules to regulate PAK1-related diseases or inhibitors to study PAK1 signaling pathway.
( Kee Wook Jung ),( Min Woo Jo ),( Seon Ha Kim ),( Woo Seung Son ),( Hyo Jeong Lee ),( Dong Hoon Yang ),( In Ja Yoon ),( So Young Seo ),( Hyun Sook Koo ),( Ji Beon Kim ),( Sang Hyoung Park ),( Kyung J 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Previous studies using Short Form-36 (SF-36) and Patient Assessment of Constipation Quality of Life (PAC-QOL) have shown a reduced quality of life (QOL) in patients with chronic constipation. However, these questionnaires were composed of more than 26 items, and these surveys taken at outpatient clinics were time-consuming. European Quality of Life-5 Dimensions (EQ-5D) is composed of 5 dimensions with 3 levels measuring people`s utility. However, the psychometric properties of EQ- 5D in chronic constipation have not been evaluated. We aimed to investigate the validity and reliability of EQ-5D and compare them with those of PAC-QOL and SF-36 in women with chronic constipation. Methods: Constipated 150 women (54 ± 16 years) who visited a constipation clinic were prospectively enrolled. They were asked to fi ll in bowel- and QOL-related questionnaires. Construct validity was examined by determining the difference betweenthe EQ-5D indexes among the questionnaires. In addition, differences in the EQ-5D index on the PAC-QOL score were analyzed. Results: The mean duration of constipation and the use of laxatives were 15.1 ± 13.6 years and 6.7 ±8.3 years, respectively. The EQ-5D index showed signifi cant differences in age, education, and comorbidities (all P< 3 times of bowel movement/week) than those with a higher frequency of defecation (= 3 times of bowel movement/week) (P Conclusions: The EQ-5D appears to be effective in measuring QOL in patients with chronic constipation. EQ-5D can be complementary to the previously used PAC-QOL and SF-36 in outpatient clinic settings.
Sung Kwon Kim,Ji Eun Park,Kyung Hwan Kim,Jin Mo Cho,문장섭,Wan-Soo Yoon,김세훈,김영일,김영준,Ho Sung Kim,도윤식,박재성,윤홍인,서영범,Kyoung-Su Sung,송진호,Chan Woo Wee,Se-Hoon Lee,임도훈,임정호,장종희,한명훈,홍제범,Kihwan Hwang,Chul-Kee Park 대한뇌종양학회 2020 Brain Tumor Research and Treatment Vol.8 No.1
Background: The Guideline Working Group of the Korean Society for Neuro-Oncology (KSNO) conducted the nationwide questionnaire survey for diverse queries facing to treat patients with brain tumor. As part III of the survey, the aim of this study is to evaluate the national patterns of clinical practice for patients with brain metastasis and primary central nervous system lymphoma (PCNSL). Methods: A web-based survey was sent to all members of the KSNO by email. The survey included 7 questions of brain metastasis and 5 questions of PCNSL, focused on the management strategies in specific situations. All questions were developed by consensus of the Guideline Working Group. Results: In the survey about brain metastasis, respondents preferred surgical resection with adjuvant treatment for patients with a surgically accessible single brain metastatic lesion less than 3 cm in size without extracranial systemic lesions. However, most respondents considered radiosurgery for surgically inaccessible lesions. As the preferred treatment of multiple brain metastases according to the number of brain lesions, respondents tended to choose radiotherapy with increasing number of lesions Radiosurgery was mostly chosen for the brain metastases of less than or equal to 4. In the survey about PCNSL, a half of respondents choose high-dose methotrexate-based polychemotherapy as the first-line induction therapy for PCNSL. The consolidation and salvage therapy showed a little variation among respondents. For PCNSL patients with cerebrospinal fluid dissemination, intrathecal chemotherapy was most preferred. Conclusion: The survey demonstrates the prevailing clinical practice patterns for patients with brain metastasis and PCNSL among members of the KSNO. This information provides a point of reference for establishing a practical guideline in the management of brain metastasis and PCNSL.
A Novel Five-Photomask Low-Temperature Polycrystalline Silicon CMOS Structure for AMLCD Application
Sang-Jin Lee,Seok-Woo Lee,Kum-Mi Oh,Soo-Jeong Park,Kyung-Eon Lee,Yong-Su Yoo,Kyoung-Moon Lim,Myoung-Su Yang,Yong-Suk Yang,Yong-Kee Hwang IEEE 2010 IEEE transactions on electron devices Vol.57 No.9
<P>A novel five-mask low-temperature polycrystalline silicon (LTPS) CMOS structure was verified by manufacturing the thin-film transistor test samples using the proposed five-mask LTPS CMOS process. In integrating the five-mask CMOS structure, a selective contact barrier metal formation process was developed, without additional photomask steps, to solve the issue of high-contact-resistance problem encountered inevitably in the contact between the indium tin oxide and doped polycrystalline silicon (poly-Si) source-drain layers. The five-mask CMOS technology was also confirmed by manufacturing a five-mask CMOS panel for the active-matrix liquid-crystal-display application.</P>
Kee, Youn Kyung,Yoon, Chan-Yun,Kim, Seung Jun,Moon, Sung Jin,Kim, Chan Ho,Park, Jung Tak,Lim, Beom Jin,Chang, Tae Ik,Kang, Ea Wha,Kie, Jeong Hae,Yoo, Tae-Hyun,Jeong, Hyun Joo,Kang, Shin-Wook,Han, Seun Williams & Wilkins Co 2017 Medicine Vol.96 No.44
<▼1><P>Supplemental Digital Content is available in the text</P></▼1><▼2><P><B>Abstract</B></P><P>Proteinuria is a major determinant of adverse renal outcome, and its reduction slows renal progression in glomerular diseases. However, the optimal target of proteinuria in glomerular diseases is unclear, and discrepancies in the definition of proteinuria produce ambiguous findings. Here we investigated the optimal target of proteinuria by using different definitions of proteinuria. We analyzed 574 IgA nephropathy (IgAN), 175 membranous nephropathy (MGN), and 177 focal segmental glomerulosclerosis (FSGS) cases from 3 Korean kidney centers. We evaluated the impact of proteinuria on renal outcome with 2 definitions: time-average proteinuria (TAP) and time-varying proteinuria (TVP). The endpoint was renal progression, defined as a 50% decline in glomerular filtration rate or end-stage renal disease. During a median follow-up of 57.3 months, the primary outcome occurred in 54 patients with IgAN, 26 with MGN, and 30 with FSGS. Multivariate Cox regression using TAP indicated that there was a linear association between proteinuria and risk of renal progression in IgAN. However, moderate proteinuria was not associated with an increased risk of renal progression in MGN and FSGS. In contrast, the analysis by TVP showed that the risk significantly increased in proportion to proteinuria during follow-up in all 3 diseases. Our findings suggest that TVP-based model can delineate association between proteinuria and risk of renal progression better than TAP-based model, considering that TVP reflects the dynamic change of proteinuria over time. Thus, proteinuria reduction to the lowest possible level is required to improve renal outcomes in patients with glomerular diseases.</P></▼2>